Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Approval Alert | Ribociclib/NSAI in HR+/HER2- Stage II-III Early Breast Cancer
Results from the NATALEE trial of ribociclib/NSAI vs NSAI alone support the approval for patients with HR-positive, HER2-negative early breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD
2
Investigators Initiate Dosing in Phase 1b/2 Trial of SNB-101 in ES-SCLC
3
107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)
4
Perioperative Durvalumab Plus Enfortumab Vedotin Improves Survival in MIBC
5